Key statistics
As of last trade Idorsia Ltd (19T:BRN) traded at 3.85, -18.85% below its 52-week high of 4.75, set on Oct 09, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 3.79 |
|---|---|
| High | 3.85 |
| Low | 3.79 |
| Bid | -- |
| Offer | -- |
| Previous close | 3.98 |
| Average volume | 2.38k |
|---|---|
| Shares outstanding | 251.51m |
| Free float | 175.27m |
| P/E (TTM) | -- |
| Market cap | 997.22m CHF |
| EPS (TTM) | -0.6593 CHF |
Data delayed at least 15 minutes, as of Feb 11 2026.
More ▼
Announcements
- Invitation to Idorsia's FY 2025 Financial Reporting webcast and conference call
- Clear route to registration positions lucerastat as the potential first oral therapy for all patients with Fabry disease
- Idorsia to present long-term lucerastat data and kidney biopsy results at WORLDSymposium
- Global expansion of Idorsia’s QUVIVIQ continues with EMS partnership for Latin America
- Idorsia to present at J.P. Morgan 2026 Healthcare Conference
- Nature Communications reports promising effect of Idorsia’s lucerastat on kidney function in Fabry disease
- Idorsia initiates a proof-of-concept trial with its oral first-in-class selective CCR6 antagonist
- Idorsia’s daridorexant in women during menopausal transition age with insomnia
- Idorsia’s JERAYGO (aprocitentan) approved in Canada for the treatment of resistant hypertension
- New Hypertension publication underscores aprocitentan’s potential in managing hypertension patients with CKD
More ▼
